• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期糖基化终产物使α-突触核蛋白发生交联——路易小体形成过程中早期的病理生理步骤?

Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation?

作者信息

Münch G, Lüth H J, Wong A, Arendt T, Hirsch E, Ravid R, Riederer P

机构信息

Neuroimmunological Cell Biology Group, Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Leipzig, Germany.

出版信息

J Chem Neuroanat. 2000 Dec;20(3-4):253-7. doi: 10.1016/s0891-0618(00)00096-x.

DOI:10.1016/s0891-0618(00)00096-x
PMID:11207423
Abstract

An excess of reactive carbonyl compounds (carbonyl stress) and their reaction products, advanced glycation endproducts (AGEs), are thought to play a decisive role in the pathogenesis of neurodegenerative disorders and Parkinson's disease (PD) in particular. Accumulation of AGEs in various intracellular pathological hallmarks of PD, such as Lewy bodies, densely crosslinked intracellular protein deposits formed from neurofilament components and alpha-synuclein, have already been described in patients in advanced stages of the disease. There is, however, no indication of the involvement of AGE-induced crosslinking of alpha-synuclein in very early stages of the disease. In this study, we observed that AGEs and alpha-synuclein are similarly distributed in very early Lewy bodies in the human brain in cases with incidental Lewy body disease. These cases might be viewed as pre-Parkinson patients, i.e. patients who came for autopsy before the possible development of clinical signs of PD. AGEs are both markers of transition metal induced oxidative stress as well as, inducers of protein crosslinking and free radical formation by chemical and cellular processes. Thus, it is likely that AGE promoted formation of Lewy bodies reflects very early causative changes rather than late epiphenomenons of PD.

摘要

过量的活性羰基化合物(羰基应激)及其反应产物——晚期糖基化终产物(AGEs),被认为在神经退行性疾病的发病机制中起决定性作用,尤其是在帕金森病(PD)中。在疾病晚期患者中,已经发现AGEs在PD的各种细胞内病理特征中积累,如路易小体,它是由神经丝成分和α-突触核蛋白形成的密集交联的细胞内蛋白质沉积物。然而,在疾病的极早期阶段,没有迹象表明AGE诱导的α-突触核蛋白交联参与其中。在本研究中,我们观察到在伴有偶然性路易小体病的人类大脑极早期路易小体中,AGEs和α-突触核蛋白的分布相似。这些病例可被视为帕金森病前期患者,即在可能出现PD临床症状之前接受尸检的患者。AGEs既是过渡金属诱导的氧化应激的标志物,也是通过化学和细胞过程诱导蛋白质交联和自由基形成的诱导剂。因此,AGE促进路易小体形成很可能反映了PD极早期的致病变化,而不是晚期的附带现象。

相似文献

1
Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation?晚期糖基化终产物使α-突触核蛋白发生交联——路易小体形成过程中早期的病理生理步骤?
J Chem Neuroanat. 2000 Dec;20(3-4):253-7. doi: 10.1016/s0891-0618(00)00096-x.
2
Synphilin-1 is present in Lewy bodies in Parkinson's disease.α-突触核蛋白-1存在于帕金森病的路易小体中。
Ann Neurol. 2000 Apr;47(4):521-3.
3
Proteomic approach to studying Parkinson's disease.蛋白质组学方法在帕金森病研究中的应用
Mol Neurobiol. 2004 Jun;29(3):271-88. doi: 10.1385/MN:29:3:271.
4
Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.帕金森病和皮质路易体病中的黑质和皮质路易小体以及营养不良性黑质神经突含有α-突触核蛋白免疫反应性。
J Neuropathol Exp Neurol. 1998 Apr;57(4):334-7. doi: 10.1097/00005072-199804000-00005.
5
Evidence of oxidative stress in the neocortex in incidental Lewy body disease.散发性路易体病新皮质中氧化应激的证据。
J Neuropathol Exp Neurol. 2005 Sep;64(9):816-30. doi: 10.1097/01.jnen.0000179050.54522.5a.
6
Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry.帕金森病中广泛存在的轴突路易神经突:α-突触核蛋白免疫细胞化学揭示的一种新病理特征。
Neurosci Lett. 1999 Apr 9;265(1):67-9. doi: 10.1016/s0304-3940(99)00208-6.
7
Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease.α-突触核蛋白免疫反应性皮质路易小体与帕金森病的认知障碍有关。
Acta Neuropathol. 2000 Sep;100(3):285-90. doi: 10.1007/s004019900168.
8
Co-association of parkin and alpha-synuclein.帕金蛋白与α-突触核蛋白的共关联
Neuroreport. 2001 Sep 17;12(13):2839-43. doi: 10.1097/00001756-200109170-00017.
9
Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function.路易小体中α-突触核蛋白的泛素化是一种与蛋白酶体功能受损无关的病理事件。
J Biol Chem. 2003 Nov 7;278(45):44405-11. doi: 10.1074/jbc.M308041200. Epub 2003 Aug 15.
10
[The mechanism of Lewy body formation in Parkinson's disease].[帕金森病中路易小体形成的机制]
Nihon Rinsho. 2000 Oct;58(10):2022-7.

引用本文的文献

1
Metabolic Dysfunction in Parkinson's Disease: Unraveling the Glucose-Lipid Connection.帕金森病中的代谢功能障碍:揭示葡萄糖 - 脂质关联
Biomedicines. 2024 Dec 13;12(12):2841. doi: 10.3390/biomedicines12122841.
2
Advanced Glycation End Products in Neurodegenerative Diseases.神经退行性疾病中的晚期糖基化终末产物
J Mol Neurosci. 2024 Dec 10;74(4):114. doi: 10.1007/s12031-024-02297-1.
3
Mitigating diabetes associated with reactive oxygen species (ROS) and protein aggregation through pharmacological interventions.通过药物干预减轻与活性氧(ROS)和蛋白质聚集相关的糖尿病。
RSC Adv. 2024 May 29;14(25):17448-17460. doi: 10.1039/d4ra02349h. eCollection 2024 May 28.
4
The Contribution of Type 2 Diabetes to Parkinson's Disease Aetiology.2型糖尿病对帕金森病病因的影响。
Int J Mol Sci. 2024 Apr 15;25(8):4358. doi: 10.3390/ijms25084358.
5
The RAGE Axis: A Relevant Inflammatory Hub in Human Diseases.RAGE轴:人类疾病中一个相关的炎症枢纽。
Biomolecules. 2024 Mar 28;14(4):412. doi: 10.3390/biom14040412.
6
Experimental and hypothetical appraisal on inhibition of glucose-induced glycation of bovine serum albumin by quercetin.槲皮素抑制葡萄糖诱导的牛血清白蛋白糖基化的实验与假说评估
J Genet Eng Biotechnol. 2023 Nov 16;21(1):123. doi: 10.1186/s43141-023-00588-5.
7
Alpha synuclein post translational modifications: potential targets for Parkinson's disease therapy?α-突触核蛋白的翻译后修饰:帕金森病治疗的潜在靶点?
Front Mol Neurosci. 2023 May 25;16:1197853. doi: 10.3389/fnmol.2023.1197853. eCollection 2023.
8
RAGE Against the Glycation Machine in Synucleinopathies: Time to Explore New Questions.在突触核蛋白病中对抗糖基化机器:是时候探索新问题了。
J Parkinsons Dis. 2023;13(5):717-728. doi: 10.3233/JPD-230070.
9
Novel dicarbonyl metabolic pathway via mitochondrial ES1 possessing glyoxalase III activity.通过具有乙二醛酶III活性的线粒体ES1的新型二羰基代谢途径。
BBA Adv. 2023 May 15;3:100092. doi: 10.1016/j.bbadva.2023.100092. eCollection 2023.
10
A Mouse Model to Test Novel Therapeutics for Parkinson's Disease: an Update on the Thy1-aSyn ("line 61") Mice.一种用于测试帕金森病新疗法的小鼠模型:Thy1-aSyn(“line 61”)小鼠的最新研究进展。
Neurotherapeutics. 2023 Jan;20(1):97-116. doi: 10.1007/s13311-022-01338-0. Epub 2023 Jan 30.